Open Nav

Please submit your session questions in advance at

Sutro Biopharma, Inc.

We have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. Our approach to discovery, without the cell, is also transcending the limitations of biologics manufacturing. Sutro has the world’s only cGMP cell-free manufacturing facility located in San Carlos, California.

  • Date:Tuesday, February 12
  • Time:11:15 AM - 11:30 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submitting Company:Sutro Biopharma
  • Submission ID:23294
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:We welcome the opportunity to provide an update on our clinical stage and preclinical programs.
  • Company
  • Company HQ City:South San Francisco
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:STRO
  • Exchange:Nasdaq
  • CEO/Top Company Official:William J Newell
  • Year Founded:2004
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:STRO-001
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):We have multiple product licensing opportunities
  • Additional Information/Comments:This state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. In addition to developing our own oncology pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are demonstrating a more efficient approach to killing tumors without harming healthy cells.
William Newell
Sutro Biopharma